Staying on Target: Reducing CV Risk by Achieving LDL-C Targets With Statin and Nonstatin Therapies

Learn the latest evidence on the comprehensive management of dyslipidemia, including the importance of achieving LDL-C targets and addressing elevated Lp(a), to reduce ASCVD risk through expert-written ClinicalThought commentaries, downloadable slides, and an on-demand webcast.

Share

Program Content

Activities

Implementing LDL-C Lowering Therapy
Call to Action: The Importance of ASCVD Risk Assessment and Achieving Targets Through Personalized LDL-C–Lowering Treatment Plans
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: April 05, 2024

Expires: April 04, 2025

Q&A on Targeting LDL-C
Expert Answers to Frequently Asked and Compelling Questions on Meeting LDL-C Targets
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: May 10, 2024

Expires: May 09, 2025

Activities

Slides on Targeting LDL-C
Staying on Target: Reducing CV Risk by Achieving LDL-C Targets With Statin and Nonstatin Therapies
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: April 15, 2024

Expires: April 14, 2025

Activities

Targeting LDL Cholesterol
Staying on Target: Reducing CV Risk by Achieving LDL-C Targets With Statin and Nonstatin Therapies
Video
Congratulations: You achieved a completion on 04/09/2022

Released: April 23, 2024

Expires: April 22, 2025

Faculty

cover img faculity

Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC

Medical Director
Center for Cardiovascular Analytics, Research, and Data Science (CARDS)
Providence Heart Institute
Providence Health System
Portland, Oregon

cover img faculity

Michael Miller, MD, FACC, FAHA

Cardiologist & Professor of Medicine
Hospital of the University of Pennsylvania
Chief of Medicine
Corporal Michael J. Crescenz VA Medical Center
Philadelphia, Pennsylvania

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by an educational grant from Novartis Pharmaceuticals Corporation.

Novartis Pharmaceuticals Corporation